S. A. Localio Laboratory, New York University School of Medicine, New York, NY 10016, USA.
Anticancer Res. 2010 Jul;30(7):2911-7.
To evaluate circulating endothelial lineage cells (ELCs) as biomarkers of tumor neovascularization in patients with pancreatic ductal adenocarcinoma (PDAC).
ELCs were isolated from the peripheral blood of patients with PDAC (n=14) or controls (n=17) before and after tumor resection/surgery and quantified using flow cytometry. Vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) were detected in tumor using immunohistochemistry and in plasma using an ELISA technique.
Circulating ELC levels were increased in patients with PDAC compared to controls. After PDAC resection, ELC levels declined. ELC level increases were associated with cancer recurrence. VEGF and PlGF were identified in cancer cells and exocrine pancreas cells. Only PlGF was detected in tumor-associated inflammatory cells. Plasma levels of PlGF were higher in patients with PDAC compared to controls.
Circulating ELCs are a potential biomarker of PDAC neovascularization, and PlGF may be an important target in treatment of PDAC.
评估循环内皮谱系细胞（ELC）作为胰腺导管腺癌（PDAC）患者肿瘤新生血管的生物标志物。
在肿瘤切除/手术后，从 PDAC 患者（n=14）和对照者（n=17）的外周血中分离 ELCs，并通过流式细胞术进行定量。使用免疫组织化学检测肿瘤中血管内皮生长因子（VEGF）和胎盘生长因子（PlGF），并使用 ELISA 技术检测血浆中 VEGF 和 PlGF。
与对照者相比，PDAC 患者的循环 ELC 水平升高。PDAC 切除后，ELC 水平下降。ELC 水平升高与癌症复发相关。VEGF 和 PlGF 被鉴定为癌细胞和外分泌胰腺细胞中的因子。仅在肿瘤相关炎症细胞中检测到 PlGF。与对照者相比，PDAC 患者的血浆 PlGF 水平更高。
循环 ELC 是 PDAC 新生血管的潜在生物标志物，PlGF 可能是 PDAC 治疗的重要靶点。
